Objective The low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio is considered to be a sensitive marker of the risk of atherosclerotic cardiovascular disease; however, in patients with a previous history of percutaneous coronary intervention (PCI), there is little information regarding the predictive value of this parameter beyond the period of early restenosis. The aim of this study was to investigate contributing factors to newly developed coronary artery disease in patients with a previous history of PCI after stabilization. Methods The clinical characteristics of 238 patients with a previous history of PCI who underwent coronary angiography following recurrent cardiac ischemia beyond the period of early restenosis were examined. Results Overall, 64% of the patients underwent late revascularization, while 31% and 50% underwent late target lesion revascularization and new lesion revascularization, respectively. A multivariate analysis identified the LDL-C/HDL-C ratio to be an independent contributor to late revascularization (hazard ratio (HR), 1.37; p<0.001). Similarly, the independent contributors to late target lesion revascularization and new lesion revascularization were the non-HDL-C level and LDL-C/HDL-C ratio, respectively. Based on the median value of the LDL-C/HDL-C ratio, the patients were classified into high and low LDL-C/HDL-C ratio groups. The logrank test revealed a significantly higher incidence of late revascularization in the high-LDL-C/HDL-C ratio group than in the low-LDL-C/HDL-C ratio group among the patients with an LDL-C level of ! 100 mg/dL (p=0.011). However, the difference between the two groups was diminished among the patients with an LDL-C level of <100 mg/dL (p=0.047), and only diabetes mellitus (HR, 2.239; p=0.009) was found to be an independent contributor to late coronary revascularization in these patients.
Introduction
Several studies have reported that in-stent restenosis rarely occurs beyond the first year after percutaneous coronary intervention (PCI) (1) (2) (3) . However, in routine clinical practice, physicians often detect severe atherosclerotic coronary dis-ease in recurrent angina patients with a previous history of PCI despite stabilization of the angina. Serial angiographic evaluations have demonstrated the occurrence of a late renarrowing phase beyond four years after stenting, while the stented segment is stabilized without early restenosis (2) . The primary mechanism underlying the development of instent restenosis in the early phase is neointimal hyperplasia; however, the mechanism of luminal narrowing in the late phase has been reported to differ from that observed in the early phase (4, 5) . Several histopathological and intracoronary optical coherence tomography studies have reported that in-stent neoatherosclerosis is frequently observed in the late phase and may contribute to the atherosclerotic progression or pathogenesis of very late stent thrombosis (4, 5) .
The effectiveness of low-density lipoprotein cholesterol (LDL-C)-lowering therapy for the primary and secondary prevention of atherosclerotic cardiovascular diseases has been established (6, 7) . Recently, it was reported that the administration of aggressive LDL-C-lowering therapy in association with statin treatment induces significant regression of the coronary plaque volume in patients with acute coronary syndrome (8) as well as stable coronary artery disease (9) . Both high serum levels of LDL-C and low serum levels of high-density lipoprotein cholesterol (HDL-C) have been recognized to be major risk factors for the development of atherosclerotic cardiovascular diseases (9, 10) . The LDL-C/ HDL-C ratio is therefore considered to be a sensitive marker of the risk of atherosclerotic cardiovascular disease (11, 12) , as it simultaneously evaluates the levels of both LDL-C and HDL-C. However, there is little information regarding the predictive value of the LDL-C/HDL-C ratio for detecting newly developed atherosclerotic cardiovascular disease beyond the early restenosis phase. In the present study, we examined factors contributing to the development of new coronary artery disease in patients with a previous history of PCI following recurrent cardiac ischemia after stabilization.
Materials and Methods
From January 2007 through December 2011, 301 consecutive patients with a previous history of PCI underwent coronary angiography for the evaluation of recurrent cardiac ischemia at Tottori Prefectural Central Hospital. The period of previous PCI in these patients was from October 1988 to October 2009. The following exclusion criteria were applied: 1) a history of coronary artery bypass grafting (25 patients), 2) a lack of follow-up coronary angiography 6-12 months after PCI (23 patients) and 3) chronic total occlusion at the time of early follow-up coronary angiography (15 patients). Overall, we enrolled 238 patients with a previous history of PCI who underwent late coronary angiography following recurrent cardiac ischemia after stabilization beyond the early phase of restenosis. Stabilization was defined as survival without any subsequent coronary revascularization at follow-up coronary angiography performed 6-12 months after the last PCI. The clinical outcomes and contributors to late coronary revascularization, including target lesion revascularization and new lesion revascularization, were examined on the late coronary angiographic examinations. Late coronary revascularization was defined as that performed after the achievement of stabilization beyond the early phase of restenosis. Data for age, gender, body mass index, risk factors for coronary artery disease, laboratory pa-rameters and cardiovascular medications prescribed at the time of admission for the late coronary angiographic examinations were obtained from a review of the hospital records or by telephone contact, and the clinical characteristics were compared between the patients with and without late coronary revascularization. With respect to the laboratory measurements, the LDL-C levels were measured according to a direct method using Cholestest LDL (Sekisui Medical, Tokyo, Japan) and the HDL-C levels were measured according to a direct method using Cholestest N HDL (Sekisui Medical). As risk factors for atherosclerotic coronary artery disease, diabetes mellitus (a medication-dependent status, a fasting plasma glucose concentration of ! 126 mg/dL and/or a hemoglobin A1c (National Glycohemoglobin Standardization Program) level of ! 6.5%), hypertension (a medicationdependent status, a systolic blood pressure of ! 140 mmHg and/or a diastolic blood pressure of ! 90 mmHg), hypercholesterolemia (a medication-dependent status and/or an LDL-C level of ! 140 mg/dL), chronic kidney disease (an estimated glomerular filtration rate of <60 mL/min/1.73m 2 ) and current smoking were examined. Similarly, the coronary angiography findings, clinical events and in-hospital mortality rates were assessed. Moreover, in order to investigate the relationship between the LDL-C/HDL-C ratio and the incidence of late coronary revascularization, the subjects were stratified into high and low LDL-C/HDL-C ratio groups according to the median value of the LDL-C/HDL-C ratio in each subgroup of study patients.
The study protocol was approved by the Ethics Committee of Tottori Prefectural Central Hospital, and the study was conducted according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines.
Statistical analysis
Continuous variables are presented as the mean ± standard deviation and were compared using Student's t-test. Categorical variables are presented as percentages and were compared using the chi-square test. Differences were considered to be statistically significant for p values of <0.05. The contributive value of late coronary revascularization was verified using the univariate Cox proportional hazards model. A multivariate Cox proportional hazards model performed according to the forward selection method was used to assess the independent roles of these variables. For the univariate analysis, the threshold for the entry of variables into each model was p<0.05. Hazard ratios (HRs) together with their 95% confidence intervals (CIs) are reported. The cumulative incidence of late coronary revascularization was analyzed using the Kaplan-Meier method with the log-rank test. The "time to event" was considered to be the period between the last PCI and the late coronary angiographic examination. All analyses were performed using the PASW Statistics Version 17.0 software program (SPSS inc., Chicago, USA). 
Results

Clinical characteristics
The clinical characteristics at the time of the late coronary angiographic examinations are shown in Table 1 . We evaluated 196 men and 42 women, with a mean age of 70.7 ± 10.2 years. Among these subjects, bare metal stents were implanted in 186 patients (78%), drug-eluting stents were implanted in 69 patients (29%) and conventional balloon angioplasty was performed in 14 patients (6%). In 31 patients (13%), both bare metal and drug-eluting stents were implanted. The average interval between the last PCI and the late coronary angiographic examination was 5.9 ± 3.7 years; in 15% of the patients, this interval was greater than 10 years. The average LDL-C/HDL-C ratio was 2.55 ± 0.98. The LDL-C/HDL-C ratio was ! 1.5 in 8% of the patients (n= 19), 1.5< LDL-C/HDL-C ratio ! 2.0 in 19% of the patients (n=46), 2.0< LDL-C/HDL-C ratio ! 2.5 in 29% of the patients (n=69) and >2.5 in 44% of the patients (n=104). During an average of 5.9 years of follow-up, 153 patients (64%) underwent additional late coronary revascularization. The patients treated with late coronary revascularization had a significantly longer interval from the last PCI to the coro-nary angiographic examination and exhibited a significantly higher incidence of diabetes mellitus and a lower incidence of β-blocker therapy compared to those treated without late coronary revascularization. Moreover, the LDL-C, non-HDL-C and HbA1c levels and LDL-C/HDL-C ratios were higher, while the HDL-C levels were lower, in the patients treated with late coronary revascularization than in those treated without late coronary revascularization.
Contributors to additional coronary revascularization subsequent to the late coronary angiographic examinations
The clinical outcomes observed at the time of the late coronary angiographic examinations are shown in Table 2 . Of the 153 patients who underwent additional late coronary revascularization, late target lesion revascularization and new lesion revascularization were performed in 73 (31%) and 118 (50%) patients, respectively. A univariate Cox proportional hazards analysis of the clinical characteristics demonstrated body mass index, diabetes mellitus, total cholesterol, LDL-C, HDL-C, non-HDL-C, the LDL-C/HDL-C ratio and HbA1c to be contributors to coronary revascularization subsequent to the late angiographic examinations ( Table 3-1) . These significant variables were included in the multivariate Cox proportional hazards model in order to assess their in- dependent roles. The multivariate analysis revealed that the LDL-C/HDL-C ratio (HR, 1.366; 95% CI, 1.181-1.579; p< 0.001) was the only independent contributor to additional late coronary revascularization. Similarly, the independent contributors to late target lesion revascularization and new lesion revascularization were the non-HDL-C level (HR, 1.010; 95% CI, 1.005-1.015; p<0.001) and the LDL-C/ HDL-C ratio (HR, 1.307; 95% CI, 1.101-1.550; p=0.002), respectively ( Table 3-2 and 3-3) . Moreover, among the patients with an LDL-C level of <100 mg/dL (n=95), the body mass index, the presence of diabetes mellitus and the HbA1c level were found to be contributors to late coronary revascularization in the univariate Cox proportional hazards analysis, while only the presence of diabetes mellitus (HR, 2.239; 95% CI, 1.227-4.086; p=0.009) was detected to be an independent contributor in the multivariate analysis (Table 4).
Comparison of patients with high and low LDL-C/ HDL-C ratios
The median value of the LDL-C/HDL-C ratio was 2.42 among all study subjects, 2.63 among the patients with an LDL-C level of ! 100 mg/dL, 2.00 among the patients with an LDL-C level of <100 mg/dL, 2.50 among the diabetic median LDL-C/HDL-C ratio : 2.42 patients, 2.25 among the non-diabetic patients, 2.27 among the patients treated with statins and 2.56 among the patients treated without statins. The patients were classified into two groups based on this median value: a high-LDL-C/HDL-C ratio group and a low-LDL-C/HDL-C ratio group. The clinical outcomes for both groups are shown in Table 2 . With respect to the clinical outcomes, the high-LDL-C/HDL-C ratio group exhibited a significantly higher incidence of additional late coronary revascularization than the low-LDL-C/ HDL-C ratio group. The rates of both late target lesion revascularization and new lesion revascularization were significantly higher in the high-LDL-C/HDL-C ratio group than in the low-LDL-C/HDL-C ratio group (42% vs. 19%, p< 0.001 and 58% vs. 41%, p=0.010, respectively). The Kaplan-Meier cumulative event curves for additional late coronary revascularization are shown in Fig. 1 . The logrank test revealed these curves to be significantly higher in the high-LDL-C/HDL-C ratio group than in the low-LDL-C/ HDL-C ratio group. This trend was maintained in both subgroups of patients treated with and without statin therapy ( Fig. 2A and B ). Further stratification of the patients with an LDL-C level of ! 100 mg/dL revealed that the high-LDL-C/HDL-C ratio group had a significantly higher incidence of late coronary revascularization than the low-LDL-C/HDL-C ratio group (p=0.011) (Fig. 2C, n=143) . However, the difference between the high-and low-LDL-C/HDL-C ratio groups was diminished in the patients with an LDL-C level of <100 mg/dL (p=0.047) (Fig. 2D, n=95 ). Among the non-diabetic patients (Fig. 2E, n=122) , late coronary revascularization occurred more frequently in the high-LDL-C/HDL-C ratio group than in the low-LDL-C/HDL-C ratio group (p=0.001); however, no such differences were noted among the diabetic patients (Fig. 2F, n=116 ).
Discussion
Our findings indicate that the LDL-C/HDL-C ratio contributes to the development of new coronary artery disease in patients with a previous history of PCI after stabilization beyond the early phase of restenosis. Furthermore, in the present study, the cumulative incidence of additional late coronary revascularization was higher in the high-LDL-C/ HDL-C ratio group than in the low-LDL-C/HDL-C ratio group. This difference was more pronounced among the patients with an LDL-C level of ! 100 mg/dL than among those with an LDL-C level of <100 mg/dL.
The effectiveness of the administration of intensive LDL-C-lowering therapy combined with statins for secondary prevention has been documented (13) . In patients treated with aggressive LDL-C-lowering therapy using statins, it has been demonstrated that the tipping point for atheromatous plaque regression is a plasma LDL-C level of <70 mg/ dL (9) . However, since atherosclerosis is a multifactorial process, not all patients with an LDL-C level of <70 mg/dL exhibit coronary plaque regression. Bayturan et al. analyzed the pooled data from 3,437 patients with established coronary artery disease and demonstrated that 21% of the patients with an LDL-C level of <70 mg/dL continued to exhibit increases in the coronary plaque volume (14) . Although LDL-C is the most important target for the preventive treatment of atherosclerotic cardiovascular disease, controlling the level of HDL-C is also considered to be important, based on the National Cholesterol Education Program and other investigations (11, 15) . Several studies have previously demonstrated an association between the LDL-C/ HDL-C ratio and coronary plaque volume regression or pro- (10, 16) . Nicholls et al. reported that statin therapy is associated with coronary plaque volume regression in patients with an LDL-C/HDL-C ratio of <1.5 and with coronary plaque volume progression in patients with an LDL-C/ HDL-C ratio of >2 (10) .
Recently, Matsumoto et al. reported follow-up results for the LDL-C/HDL-C ratios following cardiovascular events in patients treated with PCI (17) . The authors enrolled 687 consecutive patients who underwent PCI for acute coronary syndrome or stable angina and divided the subjects into three subgroups based on the LDL-C/HDL-C ratio at six months after PCI. At a median follow-up period of 33 months, they noted a lower incidence of major adverse cardiovascular events among the patients with an LDL-C/HDL-C ratio of <1.5 than among the patients with an LDL-C/ HDL-C ratio of >1.5. Taken together, these results suggest that the LDL-C/HDL-C ratio is a useful indicator for preventing the progression of atherosclerotic cardiovascular disease in angina patients. However, in that study, restenosis of the treated site comprised over 50% of the major adverse cardiovascular events. Restenosis, especially in the early phase, is highly influenced by the results of PCI, such as subsequent coronary dissection or the final minimum lumen diameter.
Our study indicated that the LDL-C/HDL-C ratio is a potentially important contributive indicator of newly developed coronary artery disease and that the high-LDL-C/HDL-C ratio group was at a high risk of late coronary revascularization. However, among the patients who achieved an LDL-C level of <100 mg/dL a therapeutic goal defined by the Japan Atherosclerosis Society Guidelines for secondary prevention (18) the predictive value of the LDL-C/HDL-C ratio was lower than that observed among the patients with an LDL-C level of ! 100 mg/dL, and diabetes mellitus was found to be a contributor to late coronary revascularization among the patients with an LDL-C level of <100 mg/dL. Moreover, no differences were noted in the cumulative incidence of late coronary revascularization between the high-and low-LDL-C/HDL-C ratio groups among the diabetic patients in our study. Diabetes mellitus is strongly related to an increased risk of coronary artery disease (19) , and the presence of diabetes mellitus was found to be an independent risk factor for the progression of coronary atheromatous plaque despite the achievement of a very low level of LDL-C ! 70 mg/dL (14) . Beyond the administration of LDL-Clowering therapy, intensive management of residual risk factors, such as diabetes mellitus, is required to prevent the development of new coronary artery disease.
It is unclear why the contribution of each variable differed between the patients treated with late target lesion revascularization and those treated with new lesion revascularization. The progression of atherosclerosis and the occurrence of restenosis in the early phase are thought to reflect different pathophysiologic processes, although several cellular processes are common to both phenomenon (20) . Moreover, the participation of chronic inflammation in the stented segment and the development of neoatherosclerosis have been reported in patients with late restenosis lesions (4, 21) . Therefore, we speculate that there are more complex pathophysiologic differences between progressive atherosclerotic lesions and late restenosis lesions, thereby explaining the differences in the contribution of each variable between late target lesion revascularization and new lesion revascularization. In the present study, the non-HDL-C level was found to be an independent contributor to late target lesion revascularization. Since the non-HDL-C level reflects the cholesterol concentration of atherogenic lipoproteins, non-HDL-C may contribute to the development of neoatherosclerosis in the stented segment.
In this study, the use of statins was not a contributing factor for late coronary revascularization. Insufficient control of the LDL-C/HDL-C ratio despite the use of statins is thought to be one reason for this finding. In order to prevent the development of new coronary artery disease, it is insufficient to only prescribe a statin, and adequately reducing the LDL-C/HDL-C ratio with statin therapy is necessary. The use of antiplatelet drugs did not reduce the incidence of late coronary revascularization in this study. Because approximately 90% of the patients were prescribed antiplatelet drugs, the limited number of study subjects prevented us from evaluating the differences between patients treated with and without antiplatelet drugs. Moreover, the use of angiotensinconverting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) was not correlated with the incidence of late coronary revascularization. In previous studies, such as the Blood Pressure Lowering Treatment Trialists' Collaboration (22) , evidence of the blood pressure-independent effects of ACE-Is on coronary artery disease has been reported; however, the effects of ARBs are not obvious. In the present study, the frequency of ARB use was twice as high as that of ACE-Is. The small ratio of ACE-Is to ARBs observed in this study is one reason why the use of ACE-Is or ARBs did not reduce the risk of late coronary revascularization. While achieving an adequately low LDL-C level is es-sential, the use of a therapeutic approach that considers multiple risk factors is necessary for the effective prevention of cardiovascular disease. Because the LDL-C/HDL-C ratio can be easily assessed in routine clinical practice, we consider it to be a potentially useful indicator for preventing the progression of atherosclerotic cardiovascular disease in angina patients. A long-term prospective large-scale study is needed to clarify whether the LDL-C/HDL-C ratio can be employed for secondary prevention in patients with angina and determine the optimal target level for the LDL-C/HDL-C ratio to effectively reduce the progression of atherosclerotic cardiovascular disease, taking into account various other risk factors.
The present study is associated with certain limitations. First, this study was a retrospective analysis conducted at a single center; therefore, the number of enrolled patients was small. Second, the indication for late coronary revascularization was determined by the attending cardiologist based on the results of coronary angiography performed at the recurrence of cardiac ischemia. Although the presence of significant stenotic lesions of the coronary artery was confirmed on coronary angiography in all patients, some patients showed no evidence of myocardial ischemia on noninvasive functional tests, especially in emergency cases. Therefore, subsequent coronary intervention is indispensable in some patients. Third, the proportion of subjects taking statins was relatively low, and the average level of LDL-C was higher than 100 mg/dL; therefore, this therapy was insufficient for secondary prevention. In the present study, most of the patients were treated by family physicians, and over half of the patients had undergone PCI more than 10 years ago. Therefore, some patients may have continued to be prescribed previous medicines without sufficient recognition of the importance of prescribing LDL-C-lowering therapy and statins. Finally, the follow-up period in this study was considerably long. Hence, the treatment strategies targeting specific risk factors may have been altered during the course of the study by the family physicians, meaning that the control of risk factors may have changed during the follow-up period.
In conclusion, the LDL-C/HDL-C ratio is an independent contributor to the development of new coronary artery disease in patients with a previous history of PCI after stabilization beyond the early phase of restenosis. In this study, the cumulative incidence of additional late coronary revascularization was higher in the patients with a high LDL-C/ HDL-C ratio than in those with a low LDL-C/HDL-C ratio. This difference was more remarkable among the patients with an LDL-C level of " 100 mg/dL than among those with an LDL-C level of <100 mg/dL.
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